October 8, 2015 News by Patricia Silva, PhD Acorda To Present New Data on MS Therapies AMPYRA and Experimental rHIgM22 at #ECTRIMS2015 Acorda Therapeutics, Inc., a company focused on therapies for neurological disorders, will present new data on its Phase 1 clinical trial evaluating rHIgM22, and five-year post-marketing safety data on AMPYRAĀ® (dalfampridine) Extended Release Tablets (10 mg) Ā at this year’sĀ 31st Congress of the European Committee for Treatment and Research in…
October 7, 2015 News by Patricia Silva, PhD Teva Pharmaceuticals to Present New Data on Multiple Sclerosis Drugs Copaxone and Laquinimod at ECTRIMS 2015 The world’sĀ largest generic medicines manufacturer,Ā Teva Pharmaceutical, is at theĀ 31st European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress currently ongoing in Barcelona, from October 7-10, 2015. Teva will be presenting the latest findings on its relapsing multiple sclerosis (MS) therapy COPAXONEĀ®Ā (glatiramer acetate injection), and product candidate for…
October 7, 2015 News by Patricia Silva, PhD ECTRIMS 2015 Congress: a Look at Young Investigator Session II The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)Ā begins today, October 7, 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress will focus heavily onĀ Teaching Courses in several topics related to multiple sclerosis (MS)…
October 7, 2015 News by Patricia Silva, PhD Genzyme to Present vs.MS Global Survey Data on Relapsing Multiple Sclerosis Challenges at ECTRIMS Genzyme recently announced a novel worldwide initiative called vs.MS, whose goal is to increase awareness of the psychical and emotional toll of relapsing multiple sclerosis (RMS) on patients and their caregivers. To enhance the comprehension of the full burden of RMS, Genzyme conducted a large-scale survey ofĀ more than 1,500 individuals…
October 7, 2015 News by Patricia Silva, PhD ECTRIMS 2015 Congress: a Look at Young Investigator Session I The 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) will start today, 7 October 2015 at the Centre de Convencions Internacional de Barcelona (CCIB) in Barcelona, Spain. The first day of the Congress is heavily focused onĀ Teaching Courses in several topics related to multiple…
October 6, 2015 News by Patricia Silva, PhD Icometrix Collaborates with Novartis on MSmetrix Software Application, New Data at Upcoming ECTRIMS 2015 Conference Icometrix, a leader in magnetic resonance imaging (MRI) biomarkers for multiple sclerosis (MS), has recently announced a collaboration agreement with Novartis Pharma AGĀ regardingĀ MSmetrix ā a measurement tool especially designed to assess brain volume and atrophy, as well as existing, new or enlarging brain lesions in MS patients. Monitoring…
October 5, 2015 News by Charles Moore Multiple Sclerosis News Today To Provide Live, On-Site Coverage Of 31st Annual #ECTRIMS2015 Congress The 31st meeting of the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (#ECTRIMS2015) is being held this week from October 7 to 10 inĀ Barcelona, Spain. The conference was last held in the Catalonian capital in 1992. Multiple Sclerosis News Today…
October 2, 2015 News by Patricia Silva, PhD Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…
September 29, 2015 News by Patricia Silva, PhD Could Genentechās Ocrelizumab Become the First Effective Primary Progressive MS Therapy? Genentech, a leading biotechnology company and member of the Roche Group, recently announced promising results on a pivotal Phase III clinical trial (ORATORIO) assessing its investigational therapyĀ ocrelizumab as a treatmentĀ for patients with primary progressive multiple sclerosis (PPMS). Multiple sclerosis (MS) is a chronic, progressive neurodegenerative disorder that results from…
September 28, 2015 News by Patricia Silva, PhD EMD Serono To Present New Data on Rebif, a Therapy for RRMS, at Upcoming ECTRIMS Congress EMD Serono, the subsidiary of Merck KGaA in the United States, recently announced that it will present new data on RebifĀ®, an interferon beta-1a therapy for relapsing-remitting multiple sclerosis (RRMS), at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), to be…
September 11, 2014 News by Patricia Silva, PhD Receptos to Present Data on RMS Treatment Trial at MSBoston 2014 Biopharmaceutical companyĀ Receptos, Inc. announced that they will review data from the phase 2 portion of theĀ RADIANCE trial,Ā the company’s phase 2 / 3 study testing RPC1063 in the treatment ofĀ Relapsing Multiple Sclerosis (RMS).Ā The data is being presented at theĀ largest meeting dedicated to multiple sclerosis…
September 9, 2014 News by Patricia Silva, PhD Genzyme’s Aubagio, Lemtrada MS Therapies To Showcase at Conference During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) taking place in Boston between September 10th and 13th, Genzyme, a Sanofi company, will present its multiple sclerosis (MS) pipeline with a new group of trial treatments for early development of MS.
August 14, 2014 News by Patricia Silva, PhD Big Multiple Sclerosis Conference Scheduled For September in Boston Just yesterday, the President of theĀ Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS),Ā Suhayl Dhib-Jalbut, publicly announced the details of this year’sĀ MSBoston2014Ā conference, in collaboration with the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). According to Dhib-Jalbut — who is also the…